All You Need To Know About GMP Manufacturing Of mRNA-LNP Drug Products

mRNA-LNP therapeutics are moving beyond vaccines into cell and gene therapy, and GMP manufacturing has to keep pace. Formulation variability grows with scale, and facilities handling large volumes of 100% ethanol face added safety and certification demands, including ATEX and IECEx. The proposed answers range from predictive models that reduce scale-up errors to real-time analytics that cut the risk of batch failure. Adam Crowe, Manager of Analytical Development at Cytiva, calls bioassays the canary in the coal mine for process development, with 30 to 40 parameters in play and ionizable and PEG lipids often synthesized at only 60% to 70% purity. Automation matters more as personalized medicine pushes toward small, individualized batches.

Access the article to examine the full take on analytics and the scale-up pairings.